書籍情報から探す
Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer. Ueda T, Shiraishi T, Ito S, et al. Sci Rep. 2021; 11: 10094.